Skip to main content
Ending the HIV epidemic in the USA: an economic modelling study in six cities.
- Author(s): Nosyk, Bohdan;
- Zang, Xiao;
- Krebs, Emanuel;
- Enns, Benjamin;
- Min, Jeong E;
- Behrends, Czarina N;
- Del Rio, Carlos;
- Dombrowski, Julia C;
- Feaster, Daniel J;
- Golden, Matthew;
- Marshall, Brandon DL;
- Mehta, Shruti H;
- Metsch, Lisa R;
- Pandya, Ankur;
- Schackman, Bruce R;
- Shoptaw, Steven;
- Strathdee, Steffanie A;
- Localized HIV Modeling Study Group
- et al.
Published Web Locationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338235/
No data is associated with this publication.
BackgroundThe HIV epidemic in the USA is a collection of diverse local microepidemics. We aimed to identify optimal combination implementation strategies of evidence-based interventions to reach 90% reduction of incidence in 10 years, in six US cities that comprise 24·1% of people living with HIV in the USA.
MethodsIn this economic modelling study, we used a dynamic HIV transmission model calibrated with the best available evidence on epidemiological and structural conditions for six US cities: Atlanta (GA), Baltimore (MD), Los Angeles (CA), Miami (FL), New York City (NY), and Seattle (WA). We assessed 23 040 combinations of 16 evidence-based interventions (ie, HIV prevention, testing, treatment, engagement, and re-engagement) to identify combination strategies providing the greatest health benefit while remaining cost-effective. Main outcomes included averted HIV infections, quality-adjusted life-years (QALYs), total cost (in 2018 US$), and incremental cost-effectiveness ratio (ICER; from the health-care sector perspective, 3% annual discount rate). Interventions were implemented at previously documented and ideal (90% coverage or adoption) scale-up, and sustained from 2020 to 2030, with outcomes evaluated until 2040.
FindingsOptimal combination strategies providing health benefit and cost-effectiveness contained between nine (Seattle) and 13 (Miami) individual interventions. If implemented at previously documented scale-up, these strategies could reduce incidence by between 30·7% (95% credible interval 19·1-43·7; Seattle) and 50·1% (41·5-58·0; New York City) by 2030, at ICERs ranging from cost-saving in Atlanta, Baltimore, and Miami, to $95 416 per QALY in Seattle. Incidence reductions reached between 39·5% (26·3-53·8) in Seattle and 83·6% (70·8-87·0) in Baltimore at ideal implementation. Total costs of implementing strategies across the cities at previously documented scale-up reached $559 million per year in 2024; however, costs were offset by long-term reductions in new infections and delayed disease progression, with Atlanta, Baltimore, and Miami projecting cost savings over the 20 year study period.
InterpretationEvidence-based interventions can deliver substantial public health and economic value; however, complementary strategies to overcome social and structural barriers to HIV care will be required to reach national targets of the ending the HIV epidemic initiative by 2030.
FundingNational Institutes of Health.
Item not freely available? Link broken?Report a problem accessing this item